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Abstract: Recent empirical findings have questioned the use of patent citations as a 
measure. This points to the need of validation of patent citations methodologies, which 
we address by testing a recent methodology for studying technological evolution, 
namely connectivity analysis of citation networks. We find connectivity analysis to be a 
valid tool to identify the reliable knowledge which opens the way to further 
technological evolution of a surgical prosthesis, the artificial spinal disc. We also 
illustrate how connectivity analysis represents how this reliable knowledge differs 
depending on the stage of technological evolution. The corroborated validity of 
connectivity analysis of patent citations may trigger a renaissance in the use of this kind 
of patent data. 
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1. INTRODUCTION. 
 
Patents are one of the main indicators used in Innovation Studies, but they present a 
fundamental problem for the study of technological evolution. One of the essential 
dimensions of technological evolution is application and use. As Walter Vincenti (2000: 
174) states ‘any complete model of technological evolution must include the physical 
real world. Artifacts, by definition, are made to ‘work’ (in some sense) in the world 
around them’. But many patents are never applied for nor used in the ‘physical real 
world’. Some patented projects are rejected because they are not sufficiently profitable 
(given the firm’s opportunity cost) to warrant development or licensee search 
(Palomeras, 2003). In other cases, patents are used for strategic objectives: to block 
rivals and to avoid being blocked, or to improve negotiating power in cross-licensing 
agreements (Hall and Ziedonis, 2001; Ziedonis, 2004). For example, Giuri et al. (2007) 
found that more than one third of European patents granted are never exploited. Thus, 
these patents cannot encompass the ‘real world’ experience, necessary to build a 
complete model of technological evolution. 
Patent citations help to gauge the importance of different patents in technological 
evolution (Trajtenberg, 1990). Moreover, a recent patent citations methodology -
connectivity analysis of patent citation networks- proposes using citations to produce a 
sequence of patents with which to trace technological evolution (Mina et al., 2007; 
Verspagen, 2007; Fontana et al., 2009; Martinelli, 2008; Batagelj, 2003). Prior to this, a 
few scientometric studies analysing networks of citations of scientific articles had 
employed connectivity as their methodology (Hummon and Doreian, 1989). 
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However, the validity of connectivity analysis, like all patent citation methodologies, is 
reduced by certain requirements of the legal system, for example, patent examiners’ 
citation additions (Alcacer and Gittelman, 2004, 2006). Alcacer and Gittelman (2004: 
26) point out that in using patent citations as a measure: ‘the strongest assumption, 
namely that a citation from patent A to patent B indicates that A used B to invent A, is 
clearly the most prone to error’. This caveat points to the importance of external 
validation of patent citation methodologies. In the present study we use the terms 
‘internal validation’ and ‘external validation’ following Jaffe and Trajtenberg’s 
definitions (2002: 9). 
By ‘internal’ validation of patent-based measures we mean the attempt to 
substantiate the hypothesized role of patent and citation-based measures as 
indicators of technological impact by examining patterns and relationships 
wholly within the patent data themselves. By contrast, ‘external’ validation 
substantiates the meaning of patent-related data by correlating patent-based 
measures with independent technological or economic indicators whose meaning 
is more self-evident. 
We believe external validation makes ‘the results compelling in a way that is much 
harder to achieve using just internal validation methods’ (Jaffe and Trajtenberg, 2002: 
10).  
 
Connectivity analysis of patent networks has been applied to the study of technical 
systems that move between different levels of aggregation (Verspagen, 2007; Fontana et 
al., 2009; Martinelli, 2008), and to examine the sequence of different product 
innovations for the treatment of a medical disease (Mina et al., 2007). However, to our 
knowledge, the present study is the first application of connectivity analysis to a single 
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product: the artificial intervertebral disc, a surgical prosthesis. This reduced 
technological scale allow us to undertake a micro-historical1 study of some of the 
patents selected by our connectivity analysis of the artificial disc to externally validate 
this recently proposed methodology. Works on connectivity analysis deal with two 
dimensions of technological evolution2: the epistemological, which is related to the 
characteristics of technological knowledge; and the socioeconomic, which is concerned 
more with the co-evolution of institutions and technology and with organizational 
strategies. Although both streams are of great interest, we focus on the epistemological 
dimension in order to concentrate our efforts for a much needed external validation. 
Concerning this technological knowledge dimension, none of these previous works can 
provide a systematic external validation of the results of connectivity analysis - 
probably due to the big scale of the problems they address- as they just provide as 
external data a broad description of the history of the technology treated. Verspagen 
(2007:94) gives a “brief primer in the technological history of fuel cells”; Fontana et al. 
(2009:313) provides a “short history and an overview of the evolution of the Ethernet 
standard base”, Martinelli (2008:1) “sum the main technological … changes of the 
telecommunication switching industry”; and Mina et al. (2007:794) give “a brief 
overview of the problem of coronary artery disease”. Thus, the main contribution of this 
paper is that we provide the first systematic external validation of the knowledge 
dimension of technological evolution as depicted by connectivity analysis. On the 
conceptual side, we will also show how connectivity analysis helps to represent how 
this knowledge differs depending on the stage of technological evolution. 
 
                                                            
1 We use this term from social history, to acknowledge the reduced scale of our historical study (Revel, 
1996) . 
2 We thank an anonymous referee for pointing this out. 
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2. THEORETICAL FRAMEWORK. 
2.1 Patent Citations and Technological Evolution 
Patent citations can be interpreted in an economic or a purely technological sense 
(Trajtenberg, 1990; Harhoff et al., 1999; Wartburg et al., 2005). The economic value of 
citations is measurable by the impact of a patent on performance measures. For firms, 
empirical studies reveal a positive relationship between the number of times that a 
patent is cited, and firm performance or stock market valuation; however, a recent work 
by Gambardella et al. (2008) have questioned convincingly the use of patent citations as 
a measurement of economic value. Technological importance can also be approximated 
by the number of times a patent is cited, and refers to the impact of the knowledge 
embodied in the patent in terms of stimulating new contributions. In this paper the focus 
is on this latter technological meaning of patent citations. For us, ‘a patent would be 
regarded as important if it opened the way to a successful line of further innovation’ 
(Trajtenberg, 1990: 184). Citations are one way to identify such patents. 
But what kind of technological knowledge opens the way to further evolution? Our 
answer is based on some of the properties of technological knowledge: we believe that 
inventors that cite other patents in their patent applications are deeply interested in the 
knowledge deriving from the physical interaction between the ‘real world’ and the 
patented product where the knowledge embedded in the patent has been used for the 
development of a commercial product. In our view, the fundamental question about 
technology – ‘Does it (or is it likely to) work?’ (Vincenti, 1990: 224)- can be answered 
in large part by the knowledge content of such ‘real world’ patents, that is, those that 
result in a practical product that is in use. These patents represent the ‘well-corroborated 
or strongly confirmed knowledge’ that provides a powerful guide for successive 
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innovations (Constant, 2000: 232). The knowledge content of these ‘real world’ patents 
acts as an ‘auto-catalyst’ (Metcalfe, 2002; Metcalfe et al., 2005) to the growth of 
subsequent knowledge, thereby enhancing technological evolution. The process of 
knowledge accumulation departs from these reliable patents, conforming sequences or 
trajectories of improvements and even new foci for inventive effort (Mina et al., 2007). 
Although this is a general claim for technological knowledge, in medical technologies 
this ‘knowledge that works’ is especially important for technological evolution. As 
Metcalfe et al. (2005: 1284) point out in their study of the evolution of intra-ocular 
lenses: ‘applications to the human body are a matter of engineering not of science; as 
with all engineering innovations, feedback from practical application is the essence of 
the development of reliable knowledge’. This practical application resides in the clinical 
use of the medical technology (Gelijns and Rosenberg, 1994). The clinical knowledge is 
significant because the interactions between artifacts and the human body are so 
complex that they cannot be fully predicted ex ante (Gelijins et al., 1998). In many 
cases, this clinical knowledge is the true source of innovation in medical technologies 
(Von Hippel, 1988).  
In our case, we use patent citations to study the technological evolution of the artificial 
disc –a surgical prosthesis used to treat spinal pain-, and the fundamental assumption is 
that this ‘reliable knowledge’ (Constant, 2002) is represented by patented artifacts 
which have been used clinically. We try to validate whether the sequence of the patents 
mapped by connectivity analysis of patent citations is based in this reliable knowledge. 
If our results prove coherent with this assumption, we will have contributed by 
advancing external validation of this new patent citation methodology.  
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In our study we pay great attention to what we call the ‘physical real world’. This is not 
to neglect the important role of social constructivism in building the selection criteria 
for inventions to become innovations,3 (Bijker et al., 1987). In fact, the clinical 
interaction between configuration of the artifact and the human body has to be approved 
by the relevant institutions such as the Food and Drug Administration (FDA) in the US, 
and the Notified Bodies of the European Commission in Europe. The FDA gives 
approval only when it considers that the ‘safety’ and the ‘efficacy’ of the devices being 
considered has been proven. The European Commission bodies are concerned only with 
‘safety’. Proof of the relevance of institutions in building the selection criteria is 
expressed in this difference, cited as the reason for the ‘slowdown of translation of those 
technologies into treatments’ in the USA compared to Europe (Miller, 2004: 2). 
But, even though socially constructed, our point is that institutionally sanctioned safety 
and/or efficacy of the knowledge signalled by these artifacts are the main pillar of 
reliable knowledge. We rely on the fact that if an implant is being used clinically, this 
implies that its physical configuration has passed all the tests and it has completed all 
the trials required by the health authorities for it to be classified as a marketable product. 
These selection criteria assure (at least for the FDA and the European Commission) the 
efficacy and/or safety of the particular artificial disc designs. 
 
2.2 Connectivity analysis of patent citation networks. 
                                                            
3 I.e., to emerge from the techno-scientific sphere to the market. 
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Connectivity analysis constitutes a set of tools for analysing patent citations. Hummon 
and Doreian (1989) proposed the first connectivity algorithm.4 They assigned a weight 
to each citation link on the basis of its position in the overall network structure. The 
method is based on the examination of the different ‘search paths’ in the network. 
Search paths are sequences of links that connect the network vertices. In Figure 1, 
patent A is cited by patent C, which in its turn is cited by patent D. A search path is 
represented by the sequence A-C-D-F-H-J, which indicates the flow of knowledge from 
patent A to patent J through several intermediate patents.  
 
- Figure 1 around here. 
 
Hummon and Doreian proposed several connectivity measures. The most used is SPNP 
(Search Path Node Pair). Consider5 the edge C-D (Figure 1). This edge connects three 
vertices (A, B, C) to the destination (D). At the same time, this edge connects its origin 
(C) to seven other vertices (D, E, F, G, H, I and J). The SPNP value is the product of 
these values (3x7=21), because it connects a total of 21 distinct pairs of vertices. The 
logic underlying this measure is that the citation links responsible for connecting higher 
numbers of patents contain the most significant knowledge flows in the citation 
network. 
Based on the work of Hummon and Doreian, Verspagen (2007) added two new 
algorithms to the connectivity analysis toolbox. The first is the ‘top path’, that is, the 
                                                            
4 Hummon and Doreian (1989) used scientific articles citations, but the methodology is the same both for 
patents and articles.  
5 This description of SPNP is built on Fontana et al. (2009). 
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sequence of patent citations from a start point to an end point, whose sum of SPNP 
value is the highest. The second is the network of the evolution of top paths (NETP). 
The NETP is constructed by joining the top paths of different temporal intervals. For 
example, there is a top path for a sample of patents in the period (t, T). Then add the 
patents published in (T, T+1). If the (t, T) patents of the (t, T+1) top path are different to 
any patent of the (t, T) top path, then the latter are no longer part of the top path, but 
they continue to be part of the NETP since they were top paths in the past. These 
patents can be seen as ‘dead ends’ where the technology cannot continue to develop 
(Martinelli, 2008, Verspagen, 2007).  
2.3 The importance of the top path and the strategic patents 
Patents do not necessarily signal innovations, as some of them are never applied on to 
the market, but remain as inventions. In this context invention can be understood in two 
ways (Arthur, 2007): invention as a mere improvement to an existing product (more 
generally, an existing technology); and invention in the form of a process which brings 
about a new product or ‘entities that depart in some sense from what went before’ 
(Arthur, 2007: 274). We will refer to them respectively as Invention 2 and Invention 1. 
The interactions between the market and the invention process differ substantially for 
these two different types. When the product to which improvements are being made by 
an invention is already on the market (Invention 2), inventors receive a ‘special 
important feedback’ (Kline and Rosenberg, 1986: 290) from the ‘real world’ experience 
of commercial use. This is especially true for medical technologies, where – as we have 
seen - regular clinical use is a powerful force driving knowledge growth. Prior to the 
first introduction of a product to the clinical market (Invention 1) the clinical knowledge 
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is less accurate, as it is based on old products which are qualitatively different from the 
new innovation (Schumpeter, 1934; Saviotti, 1996). 
On the other hand, there is general agreement about the importance of the top path, 
which represents ‘the fundamental flow of knowledge (or technological trajectory) in 
the overall network of patent citations’ (Fontana et al., 2009: 321). Similarly, 
(Martinelli, 2008: 9) states that ‘the top-path is the critical backbone of knowledge 
flow’, because according to (Mina et al., 2007: 800), it ‘summarizes the main 
technological trajectory’. However, what this means in empirical terms is not 
completely clear. Based on our theoretical argument, we would attribute this to the 
‘reliable knowledge’ content in top path patents. But this knowledge will differ 
depending on the stage of the invention-innovation dynamics represented by the top 
path. After the first innovation (in Invention 2), the reliable knowledge we search for 
exists in the sphere of commercial use and, therefore is represented by patented artifacts 
which have informed associated, real world products in use. Therefore, we would 
expect that the top path patents identified by connectivity analysis would show high 
levels of ‘innovative effectiveness’, that is, a high proportion of patents which have 
been transformed from inventions into commercial innovations.  
 
But in Invention 1 (before the first innovation), the reliable knowledge does not exist in 
the form of innovation effectiveness, since, by definition, there are no innovations in the 
market. Thus, for Invention 1 top path patents, the reliable knowledge must be gained 
through testing the performance of the product during its development (Vincenti, 2000). 
In the case of surgical prostheses, health authorities require the devices to pass several 
tests (in synthetic or animal models) and human clinical trials before allowing them to 
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become commercialized products. The broader sphere of users includes ‘vicarious6 
users’, that is, the testing engineers who are interested in whether it ‘will work’ in a 
man-made real world (i.e., the test laboratory), where they conduct R&D on the product. 
For Invention 1 top path patents we need to search for the reliable knowledge developed 
by these vicarious users. If our results are coherent for both stages of invention, we will 
have advanced the knowledge on external validation using this new patent citation 
methodology. 
 
In terms of the NETP, there is also a ‘structural’ argument related to the relevance of the 
divergent network junctions, that is, ‘strategic patents’ (Fontana et al., 2009) where two 
or more patent branches diverge. The literatures coincide in their understanding of 
divergent junctions as transitions from one technological regime to other. For example, 
in Fontana (2009: 331) a divergent junction signals the transition from invention in a 
particular device to invention in the overall technical system being studied. Martinelli 
(2008: 12) interprets the strategic divergent patent as a ‘transition from a creative 
accumulation to a creative destruction regime’ while Verspagen’s (2007: 12) 
understanding is that the divergent patent marks a transition from exploration to 
accumulation and persistence in the evolution of technological knowledge.  
 
Elaborating on the notions introduced before, we consider divergent junctions as 
transitions from Invention 1 to Invention 2. These strategic divergent patents mark the 
switch in the invention-innovation dynamics, from the stage where reliable knowledge 
                                                            
6We use the term ‘vicarious’ in the sense of ‘vicarious selection’ in the context of cultural evolution 
(Campbell, 1974). Vicarious selectors function as ‘short-cuts’, or heuristics, in a process of variation and 
selection, in which one set of criteria substitutes ‘vicariously’ for another, more direct form of selection 
(Allchin, 1999). 
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is built in the development of the product by vicarious users (Invention 1) to the stage 
where the reliable knowledge comes from the commercial use (Invention 2). 
 
 
3. THE CASE OF THE ARTIFICIAL DISC 
 
The illness we are interested in is the pain related to spinal disorders. In the US this 
condition is the main cause of pain and disability. In the 1990s, health costs in the US 
associated with this complaint accounted for an average yearly spend of $34,000 
million, not including the $16,000 million from productivity losses (Errico, 2005). 
Spinal pain is attributed most commonly to Degenerative Disc Disease (DDD), which 
includes the natural ageing processes related to the discs forming the vertebral column. 
Surgical treatment of DDD consists of the extraction of the diseased and painful disc. 
Since the 1980s, two alternative operational principles are possible (Acosta et al., 2005): 
arthroplasty, or the substitution of the articulation of the anatomical disc with an 
implantable artifact; and arthrodesis or osseous fusion, which is the extraction of the 
diseased disc and its replacement with an osseous bridge created between the two 
adjacent vertebrae. Arthrodesis has been widely used in Europe since 1980s, and in the 
US since the mid 1990s. However, arthroplasty was seen as an almost experimental 
treatment until quite recently.  
 
The implications of these two treatments are a source of uncertainty. Advocates of 
arthroplasty claim that fusing vertebrae that previously were articulated implies diverse 
biomechanical alterations to the behaviour of the vertebral column. For example, the 
movement of the fused articulations must be absorbed by the adjacent disc articulations, 
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which therefore are forced to carry a wider range of movement, which could lead to 
degeneration in these discs (the so-called ‘adjacent disc degeneration syndrome’) and 
the need for more surgical intervention (Denoziere and Ku, 2006). Procedures that use 
artificial discs are aimed at preventing the problems associated with vertebral fusion 
(Figure 2). 
 
- Insert Figure 2 around here-  
 
However, there is significant uncertainty about the relationship between fusion, 
arthroplasty and adjacent disc degeneration. Two systematic literature reviews confirm 
that in cases where arthroplasty is used there is no proof that adjacent disc degeneration 
will not occur (Kleuver et al., 2003; Freeman and Davenport, 2006). This is due in part 
to another uncertainty: it is extremely difficult to make a causal link between fusion and 
adjacent degeneration given that such degeneration could be due to the normal progress 
of degenerative disease in the other discs in the vertebral column (Freeman and 
Davenport, 2006). On the other hand, some authors, such as Lee and Langrana (2004: 
175S), believe that there is sufficient evidence to demonstrate ‘the adverse effects of 
vertebral fusion on the adjacent segments’. 
 
At the level of arthroplasty, we study the two operational principles proposed for 
replacement of the anatomical disc with a disc prosthesis. The first operational principle 
to reach the sphere of clinical use is the operational principle which we refer to as ‘hip-
like’. This operational principle is based on the design developed by Sir John Charnley 
in the 1960s for hip prostheses (Büttner-Janz, 2003). The discs have rigid contact 
surfaces and are made of similar materials to hip prostheses, i.e. metal or relatively rigid 
14 
 
plastic, such as the UHMWPE (Figure 3).The SB Charité hip-like artificial disc was the 
first artificial disc to be commercialized, in 1989. 
 
- Insert Figure 3 around here- 
 
The alternative operational principle, which we call ‘mimetic’, began to be used in 
normal clinical practice in Europe only in 2007, although the first patents were issued in 
1973 and preceded those for hip-like discs.7 Although mimetic discs had persistently 
failed to reach the sphere of use, between 1973 and 2007 numerous R&D projects were 
dedicated to the development of discs based on this operational principle (Szpalski et 
al., 2002; O’Reilly, 2008). The mimetic principle is based on the attempt to reproduce 
the mechanical properties of the anatomical disc, which has different characteristics to 
those of the hip. The hip is a synovial joint, whose movement is governed by the form 
of the contact surfaces of the bones in the articulation, and is lubricated by synovial 
fluid. However, the joint between two vertebrae is cartilaginous: this intervertebral 
fibrocartilage disc connects the vertebrae. The kinematics of the disc articulation are 
more complicated than those of the hip due to the action of this cartilaginous element 
which is situated between the bones. A healthy disc comprises two elements of different 
composition, structure and mechanical properties. In the centre of the disc is a spherical 
nucleus over which the vertebrae ‘oscillate’ (Figure 4). This oscillating movement is 
cushioned by the action of an exterior ring, the annulus fibrosus. 
 
- Insert Figure 4 around here. 
                                                            
7 At least two mimetic-type discs are currently being used in FDA approved IDE (Investigational Device 
Exemption) clinical studies. If the results of these studies are favorable these mimetic discs could be 
commercialized in the US. 
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Mimetic-type artificial discs attempt to imitate the articulation properties of the 
anatomical disc in various ways (Figure 4). However, at this level there are uncertainties 
related to these properties, which include aspects related to the movement in the joint 
(kinematics) and aspects related to the loads applied and the movement (dynamics). The 
disc has viscoelastic properties, that is, its elasticity depends on the speed at which the 
load is applied. Viscoelastic materials present hysteresis (White and Panjabi, 1978). 
Hysteresis is the phenomenon of loss of energy when a material is subjected to 
successive cycles of charge and discharge. The phenomenon was observed for the first 
time in the vertebral disc, in 1951, when Virgin tested isolated discs from cadavers. It is 
this hysteresis of the disc that led to the assumption that, in addition to governing the 
movement of the two adjacent vertebrae, the disc articulation absorbs part of the load to 
which it is subjected. Therefore, when establishing the design parameters of an artificial 
disc, advocates of the mimetic principle refer to the ‘load absorption’ properties of the 
natural disc, which the hip-like disc, due to the nature of its operational principle 
(derived from the kinematics of a perfectly rigid, solid structure without viscoelasticity), 
cannot imitate. Thus, similar to vertebral fusion, absence of the capacity to absorb load 
in hip-like discs could lead to the ‘adjacent disc degeneration syndrome’. 
 
It is at this moment that new uncertainty appears. Since Virgin’s (1951) study it has 
been proved that isolated discs (i.e., discs dissected from the vertebral column and 
studied individually) have viscoelastic properties. However, the magnitude of the 
effective load absorption in the entire vertebral column (if it exists), and in each disc 
articulation in particular, is unknown. The analogy of car wheels is illustrative: the 
viscoelastic properties of the material from which car wheels are made may be known, 
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but (if no adequate predictive models exist) only in simulations of the load conditions of 
a car, and on a predetermined surface, can the degree of load absorption of the wheel be 
assessed. In the case of the artificial disc, there are no mechanical or clinical tests 
capable of simulating conditions. As Le Huec et al. (2003) note, there are simply no 
data concerning the effective load absorption of a vertebral articulation, that is, the 
percentage of charge transmitted from one disc articulation to another. Thus, the 
theoretical arguments favouring one or other operational principles are marked by this 
fundamental uncertainty concerning the effective load absorption capacity of the disc. 
For advocates of the hip-like disc, the absorption of load in the anatomical disc (if it 
exists) is irrelevant, and the prosthetic restoration of movement is sufficient (Mayer, 
2005). For advocates of the mimetic disc, as explained above, artificial discs that do not 
absorb load, lead to degeneration in the adjacent discs (Van Ooij et al., 2003). None of 
the review studies concerning the evolution of the artificial disc reference clinical trials 
that contribute evidence in either direction. 
 
In uncertain situations, hybrids of two technologies can emerge (Geels, 2002; 
Utterback, 1994). This applies to the case of the artificial disc, for which we have 
described the high level of uncertainty about the differential performances of the hip-
like and mimetic principles; as Szpalski et al. (2002:S67) unambiguously put it, in the 
history of the artificial disc ‘of course some devices attempt to combine both 
principles’. Other documents that provide more detail on technological aspects (such as 
the state of the art review of patents US5314477 and US7250060, or US patent 
application 20050251260) also refer to the hybridization of the two principles, hip-like 
and mimetic. In our analysis, we identify hybrid patents as those whose physical 
configuration combines both operational principles. Our criteria are exemplified by 
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hybrid patent US6001130, the oldest hybrid patent, finally developed commercially as 
the Bryan Disc. 
 
- Insert Figure 5 around here- 
 
This patent has a configuration typical of the mimetic operational principle:8 two 
elastomers,9 which imitate the nucleus and the annulus in the intervertebral disc (see 
Figure 4), and two small metal plates that act as the disc-bone interface, ensuring the 
stability of the implant. However, it also incorporates an important novelty with respect 
to the typical mimetic configuration, which is that the small plates can rotate relative to 
the elastomers, as in hip-like artificial discs (Figure 5) while, in mimetic operational 
principle discs, the small plates usually are joined to the elastomers within in the same 
mould - or by means of a specific process, such as vulcanization - which leaves no 
possibility for relative rotation. 
 
4. DATA AND VALIDATION METHODOLOGY 
 
Artificial discs are represented in several US patent classes (623.17 and its subclasses; 
606.279 or 128.898); these classes refer not just to arthroplasty, but to other spinal 
implants using different operational principles, such as arthrodesis. So we built our 
database using key word searches10 and found 201 US patents granted for artificial discs 
before 2008. We searched for citations among these 201 patents. We added citations to 
                                                            
8 E.g. in patent US3867728, the oldest of the mimetic operational principle inventions and the oldest in 
the whole network. 
9 Elastomer refers to materials with mechanical properties (e.g. hysteresis) similar to rubber.  
10 We used the key words ‘disc prosthesis’, ‘artificial disc’ and ‘arthroplasty’ and conducted the search in 
the title and the abstract of the patents.  
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other kinds of medical products, to study the technological antecedents to our product 
(Mina et al., 2007). Our final database includes 1,535 patents and 6,130 citations. We 
included World Intellectual Property Office (WIPO), European and national patents in 
the cited patents, to catch the possible international origins of their antecedents.  
 
Patent citation practices reflect national and legal differences (Meyer, 2000).We use US 
patents for our artificial disc search as they are the only ones used in connectivity 
analysis so far. This geographical bias has to be considered, since Europe has played an 
important role in the history of the artificial disc. We try to catch the historical influence 
of European developments in our narration of the evolution of the artificial disc. 
However, we should point out that there is a sort of ‘autonomous’ US trajectory since 
160 of the 201 artificial disc patents are ‘pure’ US patents, that is, they belong to a 
family of patents11 associated to a US priority date or to a WIPO priority date applied in 
North America. Also, 112 of these 160 patents have European ‘offspring’,12 indicating 
that invention activity in the US has been influential in Europe; there is no reciprocal 
reverse influence, though, since of the original 201 patents only 41 have an ex-US 
origin.  
 
In Invention 2, after the first innovation appears on the clinical market, we are interested 
in the top path content of reliable knowledge based on clinical use. Therefore, in 
Invention 2 our main results are based on comparison of the artificial disc patents filed 
before April 2005 (the filing date for the most recent granted patent in our sample), and 
the artificial discs marketed up to 2006 (Table 1). We proceeded as follows: we 
                                                            
11 All documents with the same priority or combination of priorities belong to one patent family. These 
priorities could refer to national, European, US or international application dates. 
12 European or international patents which include European nations in their geographical range of 
protection. 
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collected all the commercially available artificial discs according to an industry report 
dated September 2006 (Engelhardt, 2006), and studied their physical structures based on 
the information provided in Kim et al. (2006). This is a clinical work that provides ‘an 
exhaustive review of the systems that have been proposed’ (Kim et al., 2006: xi). We 
classified the designs following the 10 criteria proposed by Miz (2006)13 and checked 
whether the designs in Kim et al. and the designs in the patents matched; this task was 
helped by the diagrams in the book and in the 53 patent documents selected by the 
connectivity algorithm.  
 
We also used another method to check the correspondence between commercial 
products and patents. We studied the history of the development of each commercial 
artificial disc in the sources mentioned in Table 1, focusing especially on product 
owners and inventors. We then checked our patent database for owners and inventors, 
and whether the patents were similar to the physical structure of the corresponding 
products, following the procedure described above. There are several cases where 
checking the owners of patents required deep historical knowledge on transactions in 
the technological market. For example, in the Prodisc case, the 2006 owner of the 
artifact was Synthes, a US public company, but the project was originally developed by 
JBS, a small French company which, in 1997, was bought by Aesculap, a German 
company. In 2000 Aesculap entered a joint venture with Viscogliosi Bros, a New York 
venture capital company, to create Spinal Solutions, a company devoted to the 
development and commercializaton of ProDisc. In 2003, Spinal Solutions was bought 
by Synthes for $350 million (Marnay, 2004; Biondo and Lown, 2004). This example 
                                                            
13 These 10 criteria cover each one 2 or more design categories. All the dimensions combined constitute a 
‘design space’ (Murmann and Frenken, 2006) of 6,384 different artifacts. 
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shows that this validation strategy requires in depth knowledge of both the technical 
aspects and the history of projects. Results and sources are presented below in Table 1. 
We found no patents for two products, Kineflex-L and Kineflex-C. We found a smaller 
proportion patents in use for the artificial disc technology than the proportion reported 
in Giuri et al. (2007). A possible explanation for this might be that this technology is far 
from maturity, as we will see in next sections; as technological and market uncertainty 
is greater in non-maturity stages, the number of abandoned projects grows (Agarwal et 
al., 2005). 
 
- Insert Table 1 around here. 
 
We double-checked only the 45 Invention 2 patents in the NETP. For the remaining 148 
Invention 2 artificial disc patents in our database, we searched for owners and inventors 
in the patents database. We then compared the physical structure of these commercial 
artificial discs with selected patents to confirm their correspondence. We did not check 
the physical structure of all 148 patents. 
 
In Invention 1, prior to the first innovation, we are interested in the presence in the top 
path of reliable knowledge developed in the performance tests conducted during 
development of the product. We searched for news about development tests in three 
scientific articles on the history of this implant (Szpalski et al., 2002; Bono and Garfin, 
2004; Sakalkale et al., 2003), and checked whether the names associated with these 
projects matched the inventors of patents prior to the first innovation. We checked this 
for the eight ‘Invention 1 patents’ in our database. 
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For the connectivity analysis of the resulting citation network we use the Citpath 
software developed by Bart Verspagen. We consulted four experts to guide our search 
and comment on our results: two vertebral column surgeons (one of whom is the 
inventor on several patents that refer to artifacts similar to those discussed here), and the 
Chief Executive Officer and head of the research and development (R&D) department 
of a company in the sector, who together represent 40 years’ of experience in the 
industry. Also, one of the authors of this paper worked in that same company for five 
years, as a manager of R&D projects. 
 
5. CONNECTIVITY ANALYSIS OF THE ARTIFICIAL DISC 
 
5.1 The network and the stages of technological evolution  
 
A network weak component is a set of patents which are connected, directly or 
indirectly, by citations.14 The artificial disc patents citation network has only one 
component, which confirms the precision of our keyword search in finding a highly 
coherent field of technology. Connectivity analysis selects 53 patents to form part of the 
NETP, and 15 to form the top path. Figures 6, 7, 8 and 9 are snapshots of the 53 patents 
selected by connectivity analysis to form the NETP for the years 1973-1987, 1973-
1997, 1973-1998 and 1973-2005. Various diagrammatic codes are included in the 
network diagrams15. The red/darker shaded nodes make up the top path of the network, 
that is, the path with the highest values of link connectivity in the network, and which 
                                                            
14 For a more detailed discussion, see Wasserman and Faust (1994: 109-110). 
15 Only the French patent FR1122634 is not a US patent in the NETP. We have decided not to include 
country codes to improve clarity in representations of the NETP and the top path thereafter for clarity 
reasons. In next figures, FR1122634’s label -situated on the top right-hand corner in Figure 9- is 
1122634. 
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constitutes part of the NETP. The yellow/lighter shaded nodes represent the remaining 
patents selected by the NETP algorithm. The square nodes correspond to patents based 
on the hip-like operational principle; the circular nodes represent patents based on the 
mimetic operational principle; the triangular nodes represent ‘hybrid’ patents. 
 
-Insert Figures 6, 7, 8 and 9 around here. 
 
The intervals of the snapshots are marked by the divergent strategic patents in the top 
path. The first important strategic patent is US4759769, filed in 1987. From this patent, 
the network split into three branches. Of these, only the branch that ends with patent 
6113637 is ‘selected’ among the post-1998 patents, being the only path along which 
knowledge flows between the two areas, pre and post-1998. After patent 6113637 there 
is a succession of small diversions from the top path due to truncation of the patent data 
in the most recent years (Verspagen, 2007; Hall and Ziedonis, 2001)16. In addition to 
these small diversions, there is a longer branch diverging from patent 6113637 which 
indicates that this is a strategic patent. 
 
In Section 2.3 we discussed the stages in the evolution of technology which are marked 
by these divergent strategic patents. The first stage is depicted in Figure 6, which shows 
the network of the evolution of top paths from 1973 to 1987. In the latter year the first 
strategic patent was applied for (US4759769). This 1973-1987 stage is clearly related to 
Invention 1 (prior to the first innovation), as the first artificial disc, the SB Charité, was 
commercialized in 1989.  
                                                            
16 We thank an anonymous referee for pointing this out. 
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The three red squares/nodes at the top right of the figure are the technological 
antecedents to the artificial disc. Patent FR1122634, US3462765 and US3593342 
describe finger and femoral prostheses which use synthetic materials similar to those 
used to construct the first mimetic artificial disc prostheses. The next patent in the top 
path is US3867728; although there is no record of use in humans of the disc prosthesis 
described in this patent, it is associated with the first animal model in the history of the 
artificial disc (Urbaniak et al., 1973). The design of this patent is repeated in several 
mimetic discs: a central piece made of an elastomer with viscoelastic properties, and 
two plates simulating the anatomic vertebral plates. 
 
The next patent in the top path (US4349921) refers to a mimetic disc owned by Dr 
David Kunz, who invented and produced this prosthesis in his hospital workshop, to 
treat pathologies of patients’ vertebral columns, and who operated on more than 300 
individuals without regulatory permission. In 1986, the health authorities barred Dr 
Kunz from practising on the basis that the operations involved a surgical procedure that 
had not been scientifically validated. Kunz’s trial showed good results from his 
surgeries and he claimed that the many citations to his patent were proof of the 
importance of his work (Jory, 2007). The next patent in the top path, US4759769, is a 
strategic patent which is analysed later. Here we point out that the artifact described is 
related to the establishment of the first systematic protocols of mechanical testing in the 
history of the artificial disc.  
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Of these three patents, two include US priority data and the third uses Canadian priority 
data.17 These three US patents are related to mimetic prostheses. In Europe, on the other 
hand, this first stage was dominated by the hip-like design. The most frequent design in 
these years was the failed prosthesis invented by Fenström (a Swedish surgeon), which 
can be considered an ‘archaic’ predecessor of the hip like principle (Bono and Garfin, 
2004: 148S). All of the 100 experimental implants conducted at the end of the 1950s 
failed in the long-run (García, 2002); we found no national or international patents 
associated with this device. Apart from this precedent, the first important hip-like 
project began in 1982 in Charité Hospital in East Berlin, when the surgeons Kurt 
Schelznack and Karin Buttner-Janz started the design of the SB Charité, the first 
artificial disc to be implanted commercially in France, in 1989. In 1986, Waldemar 
Link, a West Germany orthopaedic implants company, joined the project. The second 
artificial disc to be commercialized, marketed as Prodisc, began development in the 
early 1980s in France (Marnay, 2004). None of the four US patents referring to SB 
Charité (US5556431 and US5401269) or Prodisc (US7204852 and US5314477) were 
selected by the connectivity analysis, for either the NETP or the top path.18  
 
The second stage from 1987 to 1998, falls between the first and second strategic 
patents. In North America, two important mimetic projects were developed in these 
years in US (Szpalski et al., 2002; Bono and Garfin, 2004; Sakalkale et al., 2003). The 
Acroflex disc project was developed in 1986-1999 by Acromed, a spinal implants 
                                                            
17 The owners of these patents are US companies (US3867728), Canadian public laboratories 
(US4759769) and Canadian individuals (US4349921) 
18 There may be several patents referring to the same product. In Section 5.3 we discuss the implications 
of this for our validation exercise. 
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company in Ohio.19 The implant was employed in three experimental series in 1988, 
1993 and 2002 and Acromed applied for the first artificial disc IDE (Investigational 
Device Permission) to the FDA in order to commercialize the implant in USA following 
these clinical studies. However, the Acroflex implant failed in all three of the 
experimental series, mainly due to problems in the interface between the elastomer and 
the metallic plates, and IDE permission was withdrawn (Fraser et al., 2004).  
 
The other important mimetic project started (and abandoned) in this period was led by 
Dr Casey Lee with participation from Rutgers University and Johnson & Johnson. 
Despite exhaustive descriptions of good results from the in vitro tests conducted in the 
early 1990s, the project was abandoned because of manufacturing difficulties (Bao et 
al., 1996). Patents US5674294, US5370697 and US5320644, the yellow/light shaded 
nodes at the right side of the 1987-1998 snapshot of the NETP, show designs very 
similar to those developed in the Acromed and Lee projects (Figure 7).  
 
Following exploration of these branches based on mimetic designs until 1997, in 1998 
the top path finally chose a hip-like branch to continue the technology evolution (Figure 
8), leaving the other branches to be dead-ends where technology did not advance. In the 
years up to 1998, the first good results from SB Charité - the hip-like prosthesis - were 
published in various US scientific journals. In the first part of the 1990s SB Charité 
began diffusion to Italy and the Netherlands (Mutilescu, 2002b). In 1994, the first 
medium-term follow-up study was published, reporting good results in 93 patients 
                                                            
19 Engelhardt (2003a: 7) says that “it became part of the AcroMed culture to ridicule” SB Charité because 
its incapability to reproduce the viscoelastic behaviour of the anatomic disc. 
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(Griffith et al., 1994), and soon after, good results were reported in Italy and France 
(Cinotti et al., 1996; Lemaire et al., 1997).20 
 
All the nodes in the hip-like branch of the top path in the 1987-1998 period present a 
similar configuration, with a two-piece, hip-like articulation. Two of the four nodes in 
this branch were developed and eventually introduced to the market: patents 
US5425773 and US6113637 were commercialized in Europe in 2002 under the brand 
names ‘Maverick’ and ‘Prestige’ (Biondo and Lown, 2004) by Medtronic, a US 
company.  
 
The third and most recent stage is from 1998 to 2004 (Figure 9). This stage is marked 
historically by the consolidation of the hip-like principle in the market. Figure 10 
represents the evolution of sales of artificial discs in Europe. Besides the sales take-off 
of hip-like discs in Europe, the North American market was finally accessed: in 1997, 
Waldemar Link (the company in charge of the development and commercialization of 
the SB Charité since 1987) created Link Spine Group to introduce the prosthesis in 
North America. Also in 1997, Link attended the North American Spine Surgeons 
(NASS) Congress to present SB Charité. In 1999 an IDE application for Charité was 
made and granted by the FDA, the first successful application since Acroflex’s failed 
IDE; the experimental trials showed good results, and the FDA finally approved 
commercial utilization of an artificial disc in the US in 2004. In this same year, Biondo 
and Lown (2004: 18) state that there were:  
 
                                                            
20 Griffith et al. (1994) and Cinotti et al. (1996) published their results in Spine, the subspecialty leader 
journal for the treatment of spinal disorders. Lemaire et al. (1997) published their results in Clinical 
Orthopaedics and Related Research. Both journals were introduced to enable communication for the 
North-American associations of surgeons which eventually become international associations.  
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‘more than 2,000 international spine surgeons that have been trained on spine 
arthroplasty products, while there are more than 150 US surgeons participating in spine 
arthroplasty clinical trials. Simply put, an industry has been realized’. 
 
 
- Insert Figure 10 around here. 
 
With FDA approval for SB Charité, the trends were towards growth in the market for 
the artificial disc. As Lieberman (2004) points out, there were expectations of a ‘disc 
bubble’. For example, JP Morgan published a report which estimated that the artificial 
disc would achieve 2.8% of spinal implants market in 2005, 7.3% in 2006, 16.2% in 
2007, reaching 47.9% in 2010. This percentage would represent sales ranging from 
$1400 to $3000 million (Weinstein et al., 2003).  
 
Consolidation of clinical use of the hip like micro-paradigm is reflected in the 
composition of the top path after 1998: three of the five patents following the last 
strategic patent (US6113637) belong to the hip-like principle. Last two hybrid patents 
could reflect a future invention shift. Of the five patents in this section of the top path, 
two (US6368350 and 6986789) became a commercial product.  
 
We have seen that the top path patents reflect the different kinds of reliable knowledge 
influencing each stage of the artificial disc evolution. In the first stage, Invention 1 has 
no feedback from clinical use. Reliable knowledge comes from tests (US3867728 and 
US4759769) or other forms of vicarious use (US4349921). In the next stage, the 
transition from Invention 1 to Invention 2 is reflected at first in the persistence of 
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mimetic designs in the NETP; after 1997 the top path reflects the emergence of reliable 
knowledge in the clinical use of the hip-like principle. This trend is consolidated in the 
last stage, from 1998 to 2005, when the hip-like design becomes clinically established 
worldwide (Figure 11). 
 
- Insert Figure 11 around here. 
 
 
5.2 A tale of two (strategic) patents 
 
Figure 11 shows that divergent strategic patents mark the end and beginning of 
invention stages. The first of our divergent strategic patents is US4759769, from which 
stem the three pre-1998 branches of patents. Although the disc associated with this 
patent did not progress to the commercialization phase, it was the artificial disc design 
that was ‘most thoroughly tested’ over the years, in the course of a development project 
(Bao and Yuan, 2000: 3). The patent inventors are also the authors (Hedman et al., 
1991: S256) of the most highly cited scientific article in our patents database, which 
describes the mechanical tests devised to trial the artificial disc prosthesis described in 
the patent. It proposes the parameters for experimentation related to this prosthesis, but 
also others for artificial discs in general; the technical specifications for these tests were 
adopted 15 years later by rule F2356 of the American Society for Testing and Materials 
(ASTM) to regulate the mechanical behaviour of artificial discs (Dooris et al., 2005). 
Hedman et al. (1991: S256) emphasize the importance of in vitro trials in experiments 
on artificial discs: ‘The design-analysis redesign loop should be well travelled before 
the first clinical trial to minimize the iterations of redesign after clinical trials have 
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begun… The purpose of this paper is to present a broad range of pre-trial design 
criteria’. Thus, we would claim that the strategic status of this patent is based on its 
fundamental contribution to the reliable knowledge during the development of the 
product.  
 
The second strategic patent in our database is US6113637, the final patent in the branch 
starting from US4759769, which is selected by the post-1998 patents to connect the two 
areas of dispersion. As already mentioned, this patent is for a hip-like artificial disc. The 
Prestige disc is distinctive in that it was the first cervical disc implant in regular clinical 
use in Europe and the US. 
 
Although in most cases, our patents do not distinguish between the lumbar and cervical 
areas of the vertebral column, some prostheses are designed specifically for one or other 
of these two areas. Of the 53 patents in the NETP, 42 are designed for use in both the 
lumbar and cervical vertebral areas, for example, patent US589941, which also belongs 
to the top path and has a similar physical configuration to the Prestige disc. Four patents 
relate to designs exclusively for the lumbar area, and seven relate to prostheses for the 
cervical area, including the Prestige disc. There is no noticeably different trend given 
that three of the cervical patents were applied for before 1998 (the year of the Prestige 
disc patent application) and three were applied for after that date. 
 
However, a wider perspective again is provided by the history of real and vicarious use, 
which shows the real evolution of the artificial disc. The majority of the painful 
symptoms associated with DDD occur in the lumbar area. The first theoretical 
description in the scientific literature, of substitution of an anatomical disc with an 
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artificial implant, refers to the lumbar area (Nachemson, 1962). The first trials in 
animals (Urbaniak, 1973) and the first protocol for in vitro trials (Hedman et al., 1991) 
also refer to lumbar discs. The first discs to be commercialized (pre-1998 and pre the 
Prestige disc) were designs for the lumbar area.   
 
However, the relative simplicity of the cervical surgical technique re-focused inventive 
activity on this area in the last years (Engelhardt, 2003b). Moreover, while lumbar 
surgeries are traditionally performed only by orthopaedic surgeons, the cervical 
technique is performed by neurosurgeons, as well as orthopaedic surgeons (Mutilescu, 
2003). This resulted in increased demand for cervical treatments (Lieberman, 2004). In 
our view, the strategic position of patent US6113637 is due to the status derived by the 
Prestige disc as the first cervical disc to be used commercially, which provided reliable 
knowledge to post-1998 development projects and resulted in greater attention to the 
peculiarities of specifically cervical designs. In a 2008 industry report, 12 development 
projects for cervical discs and 6 projects for lumbar discs, were reported to be in the 
clinical trial phase (O’Reilly, 2008). 
 
Thus, both strategic patents played an important role in the history of the artificial disc. 
However, their importance is qualitatively different. Both mark the transition from 
Invention 1 to Invention 2, that is, the transition between different regimes of reliable 
knowledge. The emphasis in the first strategic patent is on the testing criteria applied 
during technological development of the product. The emphasis in the second is that it 
extends the possibilities of this procedure to many more surgeons. This change from 
‘supply’ to ‘demand’ factors highlighted by these strategic patents mimics the transition 
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from vicarious use developed in R&D projects (Invention 1) to commercial use in 
clinical procedures (Invention 2) as fundamental sources of reliable knowledge.  
 
5.3 Validation of the methodology 
 
Table 2 presents the results of our external validation exercise. We claim that the 
importance of the patents in the top path is correlated to their ‘reliable knowledge’ 
content in the different stages of technological evolution. In Invention 1, where there is 
no feedback from innovations in the market, the reliable knowledge is based on the 
results of experimental tests, prior to clinical use. The three top path artificial disc 
patents are related to prostheses proved in pre-clinical tests and irregular clinical use. 
We find no such correspondence between the other artificial discs patents in this period 
and the development projects referred to in Szpalski et al. (2002), Bono and Garfin and 
Sakalkale et al. (2003). These results are reflected in the first row of Table 2. 
 
- Insert Table 2 around here. 
 
In Invention 2, after the first innovation, feedback comes mainly from experience of 
clinical use. In the case of Invention 2, we can measure the validity of this hypothesis 
with the magnitude of ‘innovative effectiveness’. We measure the innovative 
effectiveness as the proportion of top path patents that eventually finally are 
transformed from inventions to innovations. 
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The most appealing characteristic of the patents in the Invention 2 top path (post-1987) 
is the high proportion of patents associated with products that were used clinically. 
According to our historical study (Table 1), 44% (or 4 out of 9) of the artificial disc 
patents in the Invention 2 top path, are examples of ‘innovative effectiveness’. 
 
Of the remaining NETP Invention 2 patents (36), four are for designs that are used 
regularly in clinical practice. Three of them describe incremental improvements to the 
same product. Patents US6001130 and US6156067 are continuations of patent 
US5674296, the first patent for the Bryan artificial disc. When the approval process for 
the original patent is still ongoing, a patent that is a continuation by the same inventor 
can take the priority date of the original patent once it receives final approval.21 
 
Thus, in the remaining Invention 2 NETP, ‘innovative effectiveness’ differs depending 
on whether we are counting patents or commercialized products. However, as results are 
quite similar for patents and products we deal thereafter only with products22. These 36 
patents cover 2 commercialized products (5’55% of ‘innovative effectiveness’). For the 
remaining 148 patents for artificial discs in our database ‘innovative effectiveness’ is 
4.72% (7 products for 148 patents).  
 
Thus, the measure of connectivity identified by the top path algorithm identifies reliable 
knowledge in Invention 2 patents, which have passed through all the required approval 
processes to become commercial products in regular clinical use. The remaining NETP 
                                                            
21 This information was taken on 18 October 2008 from the Manual of Patent Examining Procedure 
(MPEP), available on the US Patent and Trademark Office website: 
http://www.uspto.gov/web/offices/pac/mpep/index.htm 
22 Patents count show slightly greater “innovative effectiveness” than products count in the remaining 
NETP patents. Results for patents count are disposable by e-mailing the first author of this paper. 
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patents and the remaining patents in our database have lower and similar values for 
‘innovative effectiveness’. These results are coherent with the logic underlying the 
construction of the network and the evolution of top paths described by Martinelli 
(2008) and Verspagen (2007), in which non-top-path NETP patents are ‘dead ends’ 
where the technology cannot continue to evolve. Therefore, our results seem to 
corroborate the external validity of connectivity analysis of patent citations networks; in 
this case, it seems that the validity of connectivity analysis is not threatened by the 
interferences described by Alcacer and Gittleman (2004, 2006) since our study 
demonstrates that the top path includes a high proportion of the most important patents 
in the technological evolution of the artificial disc, that is, those which content 
technological reliable knowledge23. 
 
Table 2 present disaggregated data for the 1987-1998 and 1998-2005 Invention 2 
snapshots. The former period represents the transition from Invention 1 to Invention 2. 
There is less ‘innovative effectiveness’ in the last Invention 2 stage (1998-2005) for all 
the sections of our sample: the top path, the remaining NETP patents and the remaining 
patents in our database. Therefore, it seems more difficult for connectivity analysis to 
catch the reliable knowledge in recent patents. 
 
Although the comparison between connectivity analysis and patent citations count is not 
the main objective of this work, some comments are due. Fontana et al. (2009) show 
that the patents identified by connectivity analysis are not necessarily the most cited 
patents in the sample. In their case, 7 of the 13 top path patents are among the 20 most 
                                                            
23 In this specific case, the absence of interferences could be due also to the special characteristics of the 
medical technologies, where the share of citations added by patent examiners tends to be smaller than in 
most other sectors (Alcacer et al., 2009). We thank an anonymous referee for pointing this out. 
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cited patents in their sample. In our case, only 4 of the 14 top path patents were among 
the 20 most cited patents. It is interesting also that the two most frequently cited 
artificial disc patents are not selected by the connectivity analysis – for the NETP or the 
top path. These two patents are the initial patents for SB Charité (US 5401269) and 
ProDisc (US5314477), the first two artificial discs to be developed and used clinically 
in Europe. 
 
Fontana et al. (2009: 334, fn 22) refer to the case of a patent selected by connectivity 
analysis because of its importance ‘at that point of time’ (italics in original), meaning 
that it is what some refer to as ‘real time’ importance rather than ex-post importance 
(Consoli and Mina, 2009; Rizzo, 2000). In our case, connectivity analysis catches the 
importance of the historical contingencies of the US technological evolution, which 
originally was more focused on mimetic projects which ultimately failed. It was not 
until the late 1990s, contemporary with the first US published scientific results for 
clinical outcomes of European hip like prostheses, that the direction of US top path 
evolution changed from mimetic patents to hip like designs. This might be the reason 
for the notable absence of US patents for the SB Charité and ProDisc prostheses, which 
are the two most frequently cited patents, but which are not present in the NETP or the 
top path. The filing dated of these patents (respectively 1991 and 1993), are 
contemporaneous with the major effort in US mimetic project developments. The ex-
post success of the products associated with these two patents seems to be captured best 
by ‘pure’ patent citation count.  
 
6. CONCLUSIONS 
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Concerning the knowledge dimension of technological evolution, the historical account 
presented here seems to corroborate the external validity of connectivity analysis of 
patent citations networks. Our study demonstrates that the top path includes a high 
proportion of the most important patents in the technological evolution of the artificial 
disc, that is, those containing reliable technological knowledge. By contrast, non-top 
path patents in the network can be seen as ‘dead ends’ where the technology cannot 
continue to develop.  
 
On the conceptual side, connectivity analysis also shows how invention-innovation 
dynamics act throughout the evolution of technology, from the stage where reliable 
knowledge is built during development of the product by vicarious users (Invention 1, 
prior to the first innovation), to the stage where the reliable knowledge comes from the 
commercial use (Invention 2). In the case of the artificial disc, Invention 1 patents 
reflect the mimetic efforts of the first US development projects (1973-1987), which 
ultimately failed. In the 1987-1998 period, after the clinical introduction of the hip-like 
disc, the network of citations accounts for the transition from mimetic to hip-like 
patents. In the last stage (1998-2005), hip-like patents in the top path reflect the 
hegemony of the hip-like principle in the clinical use (Invention 2 regime).    
 
Recent works have questioned the use of patent citations as a measure (Alcacer and 
Gittelman, 2004, 2006; Gambardella et al., 2008). The validity of connectivity analysis 
of patent citations, corroborated in this work, may trigger a renaissance in the use of this 
kind of patent data. 
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Figure 1. Calculation of SPNP. The main path is in black. Source: Fontana et al. (2009) 
 
 
 
 
 
 
 
 
 
Figure 2. On the left, the fused vertebrae in an arthrodesis. On the right, the degenerated disc 
is replaced by a prosthesis. In the arthrodesis the movement of the fused articulation must be 
incorporated  into the adjacent discs (x). In the arthroplasty, the movement  is  less and similar 
to the anatomical movement (x’) (Source: US3867728).  
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Figure 3. On  the  left, a hip prosthesis. On the right, a disc prosthesis  following the  ‘ball‐and‐
socket’ principle of hip implants (Source: US6986792 and US5755796).  
 
 
 
 
 
Figure 4. The diagram on  the  left shows an anatomic  intervertebral disc. The diagram  in  the 
center shows a ‘mimetic design’ based on the reproduction of the viscoelastic properties of the 
anatomical disc, using materials  such as  synthetic elastomers  (Source: Eijkelkamp, 2002 and 
US6610094).  The  diagram  on  the  right  shows  a  representation  of  the  kinematics  of  the 
articulation. 
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Figure  5.  The hybrid patent US6001130.  Elements  20  and  22  are  elastomers,  as  in mimetic 
operational principle patents. However, instead of being joined to small plates 42 and 44, they 
move over them, as in hip‐like patents. 
 
 
 
 
 
 
Figure 6: The Network of the Evolution of Top Paths (NETP) 1973-1987 
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Figure 7: The Network of the Evolution of Top Paths (NETP) 1973-1987 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 8: The Network of the Evolution of Top Paths (NETP) 1973-1998 
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Figure 9: The Network of the Evolution of Top Paths (NETP) 1973-2004 
 
Figure 10: Artificial discs sold in 2000‐2004. 
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Figure 11. The stages of technological evolution in the top path. 
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Sources: * Industry report ** Scientific article or book chapter + Published interview with inventor. 
Table 1. Correspondence between products and patents of commercialized artificial discs.  
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 Top path Rest of the 
NETP 
Rest of the artificial 
disc patent database 
Invention 1 (content in 
reliable knowledge 
generated in product 
development). 
100% 0% 0% 
Invention 2 (innovative 
efectiveness)               
1987-1998  
50% 7.14% 8.33% 
Invention 2 (innovative 
efectiveness)               
1998-2005  
40% 0% 3,5% 
Invention 2 (innovative 
efectiveness)               
Total  
44,44% 5.55% 4.72% 
Table 2. Content of reliable knowledge in patents.  
 
 
 
 
 
 
 
 
